NCT00225784

Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer

A Phase II Trial of Cetuximab, Radiotherapy and Twice Weekly Gemcitabine in Patients With Adenocarcinoma of the Pancreas

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Dartmouth-Hitchcock Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to establish the safety and efficacy of a combination of Erbitux (cetuximab)/Gemzar (gemcitabine)/radiation in patients with pancreatic cancer.

Detailed description

The study treatment for this protocol is * Loading dose of Cetuximab 400 mg/m2 * Weekly Cetuximab 250 mg/m2 * Bi-weekly Gemcitabine 50 mg/m2 * Daily Radiation for 28 fractions * CT scan four weeks after completion of treatment * Evaluation by surgeon for resectability

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Cetuximab/Gemcitabine	Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
PROCEDURE	Radiotherapy	Daily radiotherapy for 28 days

Timeline

• Start date: 2005-02-01
• Primary completion: 2010-02-01
• Completion: 2012-09-01
• First posted: 2005-09-26
• Last updated: 2014-07-16
• Results posted: 2013-04-18